Free tool
FAERS Monitor: Vagifem
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020908 or its brand name (Vagifem, Estradiol). Reports on generic versions are filed under their own applications.
Reports
51,288
Serious
25,836
50% of reports
Hospitalization
8,336
Death reported
1,050
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,227
- headache3,188
- fatigue3,185
- nausea3,175
- off label use2,652
- pain2,331
- diarrhoea2,200
- dizziness1,956
- arthralgia1,954
- breast cancer female1,721
- dyspnoea1,714
- pruritus1,707
- rash1,678
- product adhesion issue1,541
- malaise1,501
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 562 |
| 2005 | 617 |
| 2006 | 459 |
| 2007 | 1,513 |
| 2008 | 501 |
| 2009 | 689 |
| 2010 | 1,089 |
| 2011 | 947 |
| 2012 | 1,316 |
| 2013 | 1,057 |
| 2014 | 1,323 |
| 2015 | 2,222 |
| 2016 | 2,721 |
| 2017 | 2,436 |
| 2018 | 2,790 |
| 2019 | 3,242 |
| 2020 | 3,207 |
| 2021 | 3,051 |
| 2022 | 3,260 |
| 2023 | 3,760 |
| 2024 | 3,898 |
| 2025 | 5,447 |
| 2026 | 5,180 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,002,871 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer femaleSignal | 1,721 | 28.2 | 26.8 | 42,226 |
| product adhesion issueSignal | 1,541 | 18.4 | 17.5 | 24,345 |
| headacheSignal | 3,188 | 2.1 | 2.0 | 1,859 |
| arthralgia | 1,954 | 1.9 | 1.8 | 891 |
| pruritus | 1,707 | 1.8 | 1.7 | 645 |
| fatigue | 3,185 | 1.7 | 1.6 | 907 |
| nausea | 3,175 | 1.6 | 1.6 | 836 |
| dizziness | 1,956 | 1.6 | 1.5 | 461 |
| rash | 1,678 | 1.6 | 1.5 | 364 |
| pain | 2,331 | 1.6 | 1.5 | 478 |
| malaise | 1,501 | 1.4 | 1.3 | 178 |
| diarrhoea | 2,200 | 1.4 | 1.3 | 257 |
| drug ineffective | 4,227 | 1.3 | 1.3 | 341 |
| off label use | 2,652 | 1.2 | 1.2 | 131 |
| dyspnoea | 1,714 | 1.2 | 1.2 | 83 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.